
SolarEdge reports US$326.1M revenue as fourth-quarter outlook weakens
A US$36M tariff benefit lifted gross margin, while net cash and investments slipped and fourth-quarter sales guidance came in lower.

Shoals holders would receive 1.6931 ARRAY shares per share and own about 65% of the combined company, with closing targeted for early 2027.

A US$36M tariff benefit lifted gross margin, while net cash and investments slipped and fourth-quarter sales guidance came in lower.

The reactor developer maintains its 2027 deployment target, while formal construction permit application submission remains ahead.
Shipments from Brazil to La Rochelle are expected in 2028 under an initial term through 2034, while pricing and annual tonnage remain undisclosed.
A definitive Fluor construction agreement covers three Kentucky buildings, with phased completions expected from late 2027 through mid-2028.

Management estimates up to US$2.5 million in additional survey work over two years, subject to successful delivery and further awards.

The neuroscience developer expects epilepsy safety data this quarter and FDA talks on its bipolar mania program in early 2027.

Available liquidity stood near US$700M at Sept. 30 as the company advanced a US$2.3B Great Basin expansion targeting service in late 2028.

Third-quarter revenue reached US$393.1 million, while the medical-device maker kept its annual adjusted free-cash-flow target unchanged.
The company says current assets exceeded current liabilities in October, while Australian admission still requires ASX review and approval.
The company identifies its entire Florida retail network, while federal security, inventory and recordkeeping requirements continue.
AMD's quarterly revenue reaches US$13.4 billion, while its fourth-quarter sales midpoint exceeds consensus and its margin forecast eases.
The generator forecasts US$1.5B to US$1.75B in adjusted free cash flow for 2027 as acquired plants contribute a full year.
An existing customer expands data volume by 150 per cent, but delivery timing and the exact contract value remain undisclosed.
North American production incentives contributed 416.9 billion won as storage shipments grew and European plant utilization improved.
The Alaska program tested resource gaps and extensions with 50 to 100 metre step-outs; reported intervals are core lengths with true widths unknown.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
Eagle Nuclear would issue 0.0167 shares for each Noble Plains share, with a definitive agreement still to be negotiated.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
Cash and investments fell US$41.9 million over the quarter as the gene therapy developer prepared for a potential AMT-130 launch.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
Cash reached US$48.2 million as licensing supported operations, while approaching hemp restrictions threaten current products.
River Bend targets its first data hall in the second quarter of 2027, while Beacon Point Phase 2 financing remains under evaluation.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Foremost receives C$650,000, retains 20 per cent of each property and issues five-year warrants to Denison with an ownership cap.

The companies accept 101 proposed conditions and modify 13 others, retaining four years of shareholder-funded residential bill credits.

Electrical Americas backlog reached US$16 billion as new manufacturing capacity helped lift its margin from the preceding quarter.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The company confirms federal registrations but does not disclose how many dispensaries received them or identify their locations.

The brewer has cut its U.S. footprint to six facilities, while keeping fiscal 2027 adjusted earnings guidance unchanged.

Adjusted operating income turned positive, but an insurance benefit lifted cash generation and the IFRS net loss reached C$50.8 million.

Directors retain discretion over the ratio for common and exchangeable shares, with no effective date set in the voting disclosure.